INVESTOR PROFILE | Ionic Brands

Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
https://www.ionicbrands.com/
Company:
Ionic Brands
Symbol:
CSE: IONC
Country:
United States
Sector:
Legal Recreational Marijuana
Industry:
Concentrates and Vapes
Established:
2015
Website:
https://www.ionicbrands.com/
52-Week
Range
N/A
Current
Outstanding
108,436,715
Warrants
Options
Fully Diluted
Market Cap.
14,639,000
IONIC BRANDS (CSE: IONC) has a premium portfolio of cannabis concentrate consumer brands. Ionic Brands is one of the top selling concentrate company in Washington State.
Company Brief

Ionic Brands (CSE: IONC) is creating a multi-state, consumer focused, premium cannabis porfolio consisting of iconic national brands. 

They have: 

- Stylish products

- World Class Management Team

- A proven and repeatable strategy for success

Highlights

Experienced and proven luxury cannabis concentrates brand

One of the tops selling vape brands in WA State with a loyal customer base

Largest standalone oil manufacturer in the state of WA

Consistent sales growth over 3 years with a verified marketing blueprint

Offers investors exposure to a premium luxury cannabis brand

Demonstrated to have a winning formula to become the top vape company in WA

Massive growth opportunity available with expansion into OR, NV and CA

In The News
article 1 image
Ionic Is Changing the Face of Cannabis and Creating a Social Revolution
It’s all in the URL: Ionic.social. “We believe our products are best when enjoyed in a social setting,” said co-founder Christian Struzan. READ MORE
article 2 image
Marijuana Vaping Is The Most Explosive Growth Play In Marijuana Today
“Nobody smokes marijuana anymore, they vape it.” - New York Times That's not quite true. But it will be soon. READ MORE
article 3 image
How To Invest In Marijuana Vaping
The marijuana vaporization products (or just "vape") market is set to explode in 2019. READ MORE
Related Articles

Psychedelic Toad Venom Clinical Research Boosted by $80M in Funding

2021-08-16 Benjamin M. Adams

Oxford-based startup Beckley Psytech in the United Kingdom announced August 15 that it raised $80 million to ramp up clinical trials and research using a pharmaceutical formulation of ​​5-MeO-DMT, a powerful compound produced endogenously by Sonoran Desert toad venom, to treat depression.